medigraphic.com
ISSN 0188-9796 (Impreso)

2004, Número 3

<< Anterior Siguiente >>

Rev Endocrinol Nutr 2004; 12 (3)


Osteoporosis
Posición de la Sociedad Mexicana de Nutrición y Endocrinología

Reza AAA, Vergara LA, Mendoza ZV, Martínez SC, Zúñiga GS, Porias CHL, Arechavaleta GR

Idioma: Español
Referencias bibliográficas: 70
Paginas: 126-163
Archivo PDF: 319.84 Kb.


FRAGMENTO

La osteoporosis se ha definido como una enfermedad caracterizada por una disminución en la fortaleza ósea que incrementa el riesgo de fracturas. La fortaleza ósea está determinada por la densidad mineral ósea y por el estado de la microarquitectura.
A medida que la expectativa de vida de la población se incrementa, la prevalencia de las enfermedades crónico-degenerativas aumenta de manera paralela. La osteoporosis es una de las condiciones que es muy frecuente en la población de edad avanzada y especialmente en mujeres.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Schurch MA, Rizzoli R, Mermillod B et al. A prospective study on socioeconomic aspects of fracture of the proximal femur. J Bone Miner Res 1996; 11: 1935-42.

  2. Guyatt GH. Evidence-based management of patients with osteoporosis. J Clin Densitom 1998; 1: 395-402.

  3. Cumming R, Cummings S, Nevitt M et al. Calcium intake and fracture risk: results from the study of osteoporotic fractures. Am J Epidemiol 1997; 145: 927-35.

  4. Hannan MT, Tucker KL, Dawson-Hughes B et al. Effect of dietary protein on bone loss in elderly men and women: the Framingham Osteoporosis Study. J Bone Miner Res 2000; 15: 2504-12.

  5. Heaney RP, Weaver CM. Calcium and vitamin D. Endocrinol Metab Clin N Am 2003; 32: 181-94.

  6. Heaney RP. Estrogen-calcium interactions in the postmenopause: a quantitative description. Bone Miner 1990; 11: 67-84.

  7. Riggs BL, Khosla S, Melton LJ. A unitary model for involutional osteoporosis: estrogen deficiency causes both Type I and Type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Mineral Res 1998; 13: 763-73.

  8. Falahati-Nina A, Riggs BL, Atkinson EJ et al. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 2000; 106: 1553-60.

  9. Shea B, Wells G, Cranney A et al. VII. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocrine Reviews 2002; 23(4): 552-9.

  10. Chevalley T, Rizzoli R, Nydegger V et al. Effects on calcium supplements on femoral bone mineral density and vertebral fracture rate in vitamin-D-replet elderly patients. Osteoporosis Int 1994; 4: 245-52.

  11. Reid IR, Ames RW, Evans MC et al. Effect of calcium supplementation on bone density in postmenopausal women. N Engl J Med 1993; 328: 460-64.

  12. Recker R, Hinders S, Daves M et al. Correcting calcium nutritional deficiency prevents spine fractures in elderly women. J Bone Miner Res 1996; 11: 1961-6.

  13. Riggs BL, O´Fallon MW, Muhs J et al. Long term effects of calcium supplementation on serum parathyroid hormone levels, bone turnover, and bone loss in elderly women. J Bone Miner Res 1998; 13: 168-74.

  14. Hansson T, Roos B. The effect of fluoride and calcium on spinal bone mineral content: a controlled, prospective (3 years) study. Calcif Tissue Int 1987; 40: 315-7.

  15. Davis JW, Ross PD, Johnson NE et al. Estrogen and calcium supplement use among Japanese-American women: effects upon bone loss when used singly and in combination. Bone 1995; 17: 369-73.

  16. Nieves JW, Komar L, Cosman F et al. Calcium potentiates the effect of estrogen and calcitonin on bone mass; review and analysis. Am J Clin Nutr 1998; 67: 18-24.

  17. Honkanen RJ, Alhava E, Saarikoski S et al. Interaction of calcium and HRT in the prevention of bone loss and fractures in early postmenopausal women. J Bone Miner Res 1999; 14 (suppl 1): S181.

  18. NIH Consensus Conference. Optimal calcium intake. JAMA 1994; 272: 1942-8.

  19. Häuselmann HJ, Rizzoli R. A comprehensive review of treatments for postmenopausal osteoporosis. Osteoporosis Int 2003; 14: 2-12.

  20. The osteoporosis methodology group and the osteoporosis research advisory group. Meta-analyses of therapies for postmenopausal osteoporosis. Endocrine Reviews 2002; 23 (4): 496-507.

  21. Heaney RP, Barger-Lux MJ, Dowell MS et al. Calcium absorptive effects of vitamin D and its major metabolites. J Clin Endocrinol Metab 1997; 82: 4111-6.

  22. Devine A, Wilson SG, Dick IM et al. Effects of vitamin D metabolites on intestinal calcium absorption and bone turnover in elderly women. Am J Clin Nutr 2002; 75: 283-8.

  23. Papadimitropoulos E, Wells G, Shea B et al. VIII: Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocrine Reviews 2002; 23 (4): 560-9.

  24. Heaney RP. Nutritional factors in osteoporosis. Annu Rev Nutr 1993; 13:287-316.

  25. Chapuy MC, Arlot ME, Duboeuf F et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 1992; 327: 1637-42.

  26. Dawson-Hughes B, Harris S, Krall E, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337: 670-6.

  27. Peacock M, Liu G, Carey M et al. Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60. J Clin Endocrinol Metab 2000; 85: 3011-9.

  28. Wells G, Tugwell P, Shea B et al. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocrine Reviews 2002; 23 (4): 529-39.

  29. Khosla S, Bilezikian JP. The Role of estrogens in men and androgens in women. Endocrinol Metab Clin N Am 2003; 32: 195-218.

  30. Torgerson DJ, Bell-Syer SEM. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 2001; 285:2891-7.

  31. Hulley S, Grady D, Furberg C et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-13.

  32. Herrington DM, Reboussin DM, Brosnihan B et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000; 343: 522-9.

  33. Viscoli CM, Brass LM, Kernan WN et al. A clinical trial of estrogen-replacement therapy after isquemic stroke. N Engl J Med 2001; 345: 1243-9.

  34. Wassertheil-Smoller S, Hendrix SL, Limancher L et al (WHI Investigators). Effect of estrogen plus progestin on stroke in postmenopausal women: the Women´s Health Initiative: a randomized trial. JAMA 2003; 289 (20): 2673-84.

  35. Anderson GL, Limacher M, Assaf AR et al (WHI steering committee). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women´s Health Initiative randomized controlled trial. JAMA 2004; 291(14): 1769-71.

  36. Writing Group for the Women´s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women´s Health Initiative Randomized Controlled Trial. JAMA 2002; 288: 321-33.

  37. Anderson GL, Judd HL, Kaunitz AM et al (WHI Investigators). Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women´s Health Initiative randomized trial. JAMA 2003; 290(13): 1739-48.

  38. Kim C, Kwok Y. Decision analysis of hormone replacement therapy after the Women´s Health Initiative. Am J Obstet Gynecol 2003; 189: 1228-33.

  39. Cranney A, Tugwell P, Zytaruk N et al. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocrine Reviews 2002; 23 (4): 524-8.

  40. Fontana A, Delmas P. Selective estrogen receptors modulators in the prevention and treatment of postmenopausal osteoporosis. Endocrinol Metab Clin N Am 2003; 32: 219-32.

  41. Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with Raloxifene. JAMA 1999; 282: 637-45.

  42. Cauley JA, Norton L, Lippman LE et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breat Cancer Res Treat 2001; 65: 125-34.

  43. McClung MR. Bisphosphonate. Endocrinol Metab Clin N Am 2003; 32: 253-71.

  44. Cranney A,Wells G, Willan A et al. II Meta-analysis of alendronato for the treatment of postmenopausal women. Endocrine Reviews 2002; 23 (4): 508-16.

  45. Schnitzer T, Bone HG, Crepaldi G et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging (Milano) 2000; 12: 1-12.

  46. Ravn P, Bidstrup M, Wasnich RD et al. Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized controlled trial. Ann Intern Med 1999; 131: 935-42.

  47. Ravn P, Weiss SR, Rodriguez-Portales JA et al. Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. J Clin Endocrinol Metab 2000; 85: 1492-7.

  48. Orwoll E, Ettinger M, Weiss S et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343: 604-10.

  49. Adachi JD, Saag KG, Delmas PD et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids; a randomized, double-blind, placebo controlled extension trial. Arthritis Rheum 2001; 44: 202-11.

  50. Cranney A, Tugwell P, Adachi J et al. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocrine Reviews 2002; 23(4): 517-23.

  51. Mortensen L, Charles P, Bekker PJ et al. Risedronate increases bone mass in an early postmenopausal population : two years of treatment plus one year of follow-up. J Clin Endocrinol Metab 1998; 83: 396-402.

  52. Brown JP, Kendler DL, McClung MR et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002; 71: 103-11.

  53. Wallach S, Cohen S, Reid DM et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000; 67: 277-85.

  54. Tonino RP, Meunier PJ, Emkey R et al. Skeletal benefits of alendronate : 7-year treatment of postmenopausal osteoporotic women. Phase III osteoporosis treatment study group. J Clin Endocrinol Metab 2000; 85: 3109-15.

  55. Silverman SL. Calcitonin. Endocrinol Metab Clin N Am 2003; 32: 273-84.

  56. Cranney A, Tugwell P, Zytaruk N et al. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocrine Reviews 2002; 23(4): 540-51.

  57. Chesnut CH, Silverman SL, Andriano K et al. Prospective, randomized trial of nasal spray calcitonin in postmenopausal women with established osteoporosis; the PROOF study. Am J Med 2000; 109: 267-76.

  58. Trovas GP, Lyritis G, Galanos A et al. A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers. J Bone Miner Res 2002; 17: 521-7.

  59. Rubin MR, Bilezikian JP. New anabolic therapies in osteoporosis. Endocrinol Metab Clin N Am 2003; 32: 285-307.

  60. Riggs BL, Hodgson SF, O´Fallon WM et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990; 322: 802-9.

  61. Pak CY, Sakhaee K, Adams-Huet B et al. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride: final report of a randomized controlled trial. Ann Intern Med 1995; 123: 401-8.

  62. Pak CY, Zerwekh JE, Antich PP et al. Slow-release sodium fluoride in osteoporosis. J Bone Miner Res 1996; 11: 561-4.

  63. Meunier PJ, Roux C, Seeman E et al. The effects of Strontium Ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004; 350: 459-68.

  64. Fuleihan GE. Strontium Ranelate- A novel theraphy for osteoporosis or a permutation of the same. N Engl J Med 2004; 350: 504-6.

  65. Fisher W J, Cummings S R, Greenspan S. New treatments for growing scourge of brittle bones. Annals of Intern Med 2004; 140(2): 153-6.

  66. Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-41.

  67. Deal C. The use of intermittent human parathyroid hormone as a treatment for osteoporosis. Curr Rheumatol Rep 2004; 6(1): 49-58.

  68. Doggrell SA. Does the combination of alendronate and parathyroid hormone give a greater benefit than either agent alone in osteoporosis? Expert Opin Pharmacother 2004; 5(4): 955-8.

  69. Horwitz MJ, Tedesco MB, Gundberg C et al. Short term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2003; 88: 569-75.

  70. Guyatt GH, Cranney A, Griffith MS et al. Summary of meta-analyses of therapies for postmenopausal osteoporosis and the relationship between bone density and fractures. Endocrinol Metab Clin N Am 2002; 31: 659-79.




2020     |     www.medigraphic.com